Jianmin Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
Jianmin Pharmaceutical Group Co Ltd cash flow-to-debt ratio. Jianmin Pharmaceutical Group Co Ltd (600976) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of CN¥106.82 Million could theoretically repay 0% of its total liabilities (CN¥1.81 Billion) in one year. Check Jianmin Pharmaceutical Group Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jianmin Pharmaceutical Group Co Ltd (2003–2025)
Cash flow-to-debt ratio of Jianmin Pharmaceutical Group Co Ltd from 2003 to 2025. Historical debt coverage capacity for Jianmin Pharmaceutical Group Co Ltd across 23 annual periods. Check cash flow reinvestment rate of Jianmin Pharmaceutical Group Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Jianmin Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2025)
Jianmin Pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Jianmin Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see Jianmin Pharmaceutical Group Co Ltd operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | CN¥274.53 Million | CN¥1.81 Billion | ▲ +18.6% |
| 2024 | 0.13x | CN¥234.27 Million | CN¥1.83 Billion | ▼ -8.7% |
| 2023 | 0.14x | CN¥268.39 Million | CN¥1.91 Billion | ▲ +2.1% |
| 2022 | 0.14x | CN¥215.87 Million | CN¥1.57 Billion | ▼ -33.3% |
| 2021 | 0.21x | CN¥259.18 Million | CN¥1.26 Billion | ▲ +79.6% |
| 2020 | 0.11x | CN¥125.54 Million | CN¥1.09 Billion | ▲ +11.1% |
| 2019 | 0.10x | CN¥74.45 Million | CN¥720.63 Million | ▼ -6.3% |
| 2018 | 0.11x | CN¥63.60 Million | CN¥577.11 Million | ▲ +155.7% |
| 2017 | 0.04x | CN¥35.20 Million | CN¥816.71 Million | ▼ -70.6% |
| 2016 | 0.15x | CN¥113.84 Million | CN¥776.45 Million | ▲ +83.0% |
| 2015 | 0.08x | CN¥48.45 Million | CN¥604.72 Million | ▼ -57.7% |
| 2014 | 0.19x | CN¥103.23 Million | CN¥544.79 Million | ▲ +110.9% |
| 2013 | 0.09x | CN¥45.36 Million | CN¥504.92 Million | ▼ -67.3% |
| 2012 | 0.27x | CN¥98.17 Million | CN¥357.90 Million | ▲ +205.8% |
| 2011 | -0.26x | CN¥-75.54 Million | CN¥291.28 Million | ▼ -139.5% |
| 2010 | 0.66x | CN¥150.08 Million | CN¥228.78 Million | ▲ +368.0% |
| 2009 | 0.14x | CN¥66.69 Million | CN¥475.79 Million | ▼ -49.4% |
| 2008 | 0.28x | CN¥110.11 Million | CN¥397.80 Million | ▲ +675.4% |
| 2007 | -0.05x | CN¥-6.88 Million | CN¥143.07 Million | ▼ -124.4% |
| 2006 | 0.20x | CN¥56.18 Million | CN¥285.18 Million | ▲ +271.4% |
| 2005 | -0.11x | CN¥-34.63 Million | CN¥301.33 Million | ▼ -710.1% |
| 2004 | 0.02x | CN¥4.13 Million | CN¥219.38 Million | ▲ +9.0% |
| 2003 | 0.02x | CN¥4.19 Million | CN¥242.31 Million | — |